Early Intervention for Postpartum PTSD: Comparing Written Exposure and Capnometry-Guided Breathing Therapy - Phase 2
Early Intervention for Postpartum PTSD: Comparing Written Exposure and Capnometry Guided Breathing Therapy - Phase 2
The purpose of this study is to evaluate the feasibility, acceptability, and preliminary effectiveness of two early interventions, Written Exposure Therapy (WET) and Capnometry-Guided Breathing Intervention (CGRI), for reducing post-traumatic stress disorder (PTSD) symptoms following childbirth, compared with usual care.
調査の概要
状態
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72205
- University of Arkansas for Medical Sciences
-
コンタクト:
- Heather Moody
- 電話番号:501-526-4333
- メール:HLMoody@uams.edu
-
-
California
-
Palo Alto、California、アメリカ、94304
- Stanford University
-
コンタクト:
- Guillermina Ferrea
- 電話番号:(650) 457 7704
- メール:gferrea@stanford.edu
-
コンタクト:
- Aleesha Jethwa
- 電話番号:+44 7857 907762
- メール:Ajethwa1@stanford.edu
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥18
- Delivered a live infant within 5 days
- Severe maternal morbidity or infant admitted to NICU
- PCL-5 ≥28
- English-speaking
- Able to consent and participate
Exclusion Criteria:
- Active psychosis or mania
- Current suicidal crisis
- Current suicidal intent or plan
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Written Exposure Therapy (WET)
Participants will complete 5 writing sessions. One 50-minute session will be held in the hospital before discharge, followed by four 50-minute sessions by secure video once a week. Sessions are delivered by a trained study therapist under licensed clinician supervision. |
Participants will complete 5 writing sessions. One 50-minute session will be held in the hospital before discharge, followed by four 50-minute sessions by secure video once a week. Sessions are delivered by a trained study therapist under licensed clinician supervision. |
|
実験的:Capnometry-Guided Breathing Intervention (CGRI)
Participants will complete one 45-minute in-hospital training session using the device, which includes a tablet and breathing sensor. They will then practice guided breathing at home twice daily for about 17 minutes each time for 4 weeks, with weekly phone check-ins from study staff. |
Participants will complete one 45-minute in-hospital training session using the device, which includes a tablet and breathing sensor. They will then practice guided breathing at home twice daily for about 17 minutes each time for 4 weeks, with weekly phone check-ins from study staff. |
|
介入なし:Postpartum Standard of Care
Participants will follow their current standard of care. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
書面曝露療法(WET)を完了した参加者の割合
時間枠:ベースラインから6週目まで
|
ベースラインから6週目まで
|
|
|
書面による曝露療法(WET)への遵守率
時間枠:ベースラインから第6週まで
|
ベースラインから第6週まで
|
|
|
カプノメトリー誘導呼吸介入(CGRI)を完了した参加者の割合
時間枠:ベースラインから6週目まで
|
ベースラインから6週目まで
|
|
|
カプノメトリーガイド呼吸介入(CGRI)への遵守率
時間枠:ベースラインから6週目まで
|
ベースラインから6週目まで
|
|
|
Percentage of participants initiating assigned treatment
時間枠:Baseline (up to 2 weeks)
|
Proportion of participants who begin their assigned intervention (≥1 session for WET; completion of initial training for CGRI) |
Baseline (up to 2 weeks)
|
|
Participant Satisfaction Scale Score using Client Satisfaction Questionnaire (CSQ-8)
時間枠:Week 5
|
Participant satisfaction measured using the CSQ-8 questionaire, an 8-item scale. (Scale score 8 - 32. Higher scores represent greater satisfaction with treatment.) |
Week 5
|
|
Treatment credibility using the Opinion About Treatment (OAT) form
時間枠:Week 5
|
Participant perceptions of treatment credibility will be measured using the OAT form. (Scale score 3 - 27. Higher scores represent greater perceived credibility of the intervention.) |
Week 5
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from baseline in PTSD Checklist for DSM-5 (PCL-5) Scale Score
時間枠:Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
Change in PTSD symptoms during past week measured by the PTSD Checklist for DSM-5 (PCL-5), a 20-item self-report measure. (Score range 0 - 80, higher scores indicating greater severity of PTSD symptoms.). |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
|
Change from baseline in Edinburgh Postnatal Depression Scale (EPDS) Scale Score
時間枠:Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
Participants complete the EPDS questionnaire, a 10-item scale assessing postpartum depressive symptoms over the past 7 days. (Score range 0 - 30, higher scores represents greater symptom severity.) |
Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6, Week 12
|
|
Change from baseline in Whole Person Health Index (WPHI) Scale Score
時間枠:Baseline, Week 3, Week 6, Week 12
|
Participants complete WHPI questionaire, a 9 item scale assessing global health and functioning. (Score range 9 - 81, higher scores represent better health). |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Generalized Anxiety Disorder Questionaire (GAD-7)
時間枠:Baseline, Week 3, Week 6, Week 12
|
Participants complete the GAD-7, a 7-item scale assessing anxiety symptoms over 2 weeks. (Score range 0 - 21, higher scores represent greater anxiety severity.) |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Maternal-infant bonding (MIBS) Scale Score
時間枠:Baseline, Week 3, Week 6, Week 12
|
Participants complete the MIBS questionaire, an 8 item measure of bonding difficulties over the past few weeks (Score range 0 - 24, higher scores represent greater bonding impairment). |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in STanford Obstetric Recovery checKlist (STORK) scale score
時間枠:Baseline, Week 3, Week 6, Week 12
|
Participants complete the STORK questionnaire, a 47-item scale assessing postpartum recovery over the past 7 days. (Score range 0 - 188, higher score represents a greater degree of recovery) |
Baseline, Week 3, Week 6, Week 12
|
|
Change from baseline in Breastfeeding Self-Efficacy Scale-Short Form (BFSES-SF)
時間枠:Baseline, Week 3, Week 6, Week 12
|
Participants complete the BFSES-SF, a 14-item measure of breastfeeding self-efficacy (Score range 14 - 70, higher scores indicate greater breastfeeding confidence.) |
Baseline, Week 3, Week 6, Week 12
|
|
Percentage of participants completing hair sample collection at Baseline and Week 6
時間枠:Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. |
Baseline, Week 6
|
|
Change in hair cortisol concentration between Baseline and Week 6
時間枠:Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair cortisol concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair cortisone concentration between Baseline and Week 6
時間枠:Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair cortisone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair testosterone concentration between Baseline and Week 6
時間枠:Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair testosterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair progesterone concentration between Baseline and Week 6
時間枠:Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair progesterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair corticosterone concentration between Baseline and Week 6
時間枠:Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair corticosterone concentration from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair dehydroepiandrosterone (DHEA) concentration between Baseline and Week 6
時間枠:Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair dehydroepiandrosterone (DHEA) concentration values from Baseline to Week 6 |
Baseline, Week 6
|
|
Change in hair androstenedione concentration between Baseline and Week 6
時間枠:Baseline, Week 6
|
Participants have hair samples collected at baseline and at Week 6 post treatment. Hair steroid concentrations reflect average systemic hormone exposure over the preceding weeks. Change in hair androstenedione concentration from Baseline to Week 6 |
Baseline, Week 6
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Pervez Sultan、Stanford University
- 主任研究者:Debra Kaysen、Stanford University
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 80498-2
- R01AT013866-01 (米国 NIH グラント/契約)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).
IPD 共有時間枠
Beginning 9 months and ending 36 months following article publication.
IPD 共有アクセス基準
Wish whom? Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. For what types of analysis? For individual participant data meta-analysis By what mechanism will data be made available? Proposals may be submitted up to 36 months following article publication. After 36 months the data will be available in our University's data warehouse but without investigator support other than deposited metadata. Information regarding submitting proposals and accessing data may be found at (Link to be provided).
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。